米鲁姆制药

最新新闻

• 评级变动
  TD Cowen Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140
  \u5e02\u573a\u8d44\u8baf · 2026/8/10
• 评级变动
  RBC Capital Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $148
  \u5e02\u573a\u8d44\u8baf · 2026/7/7
• 评级变动
  Analysts Are Bullish on These Healthcare Stocks: Maze Therapeutics, Inc. (MAZE), Mirum Pharmaceuticals (MIRM)
  TipRanks · 2026/9/10
• 评级变动
  A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $118 to $140
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• 评级变动
  J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $125
  \u5e02\u573a\u8d44\u8baf · 2026/7/2
• 评级变动
  Citi Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $145
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 评级变动
  A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $135 to $140
  \u5e02\u573a\u8d44\u8baf · 2026/8/6
• Baird Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Raises Target Price to $130
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $130 to $195
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $118
  \u5e02\u573a\u8d44\u8baf · 2026/8/11
• 评级变动
  J.P. Morgan Keeps Their Buy Rating on Mirum Pharmaceuticals (MIRM)
  TipRanks · 2026/8/11
• 评级变动
  H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $185
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $195
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  A Quick Look at Today's Ratings for Mirum Pharmaceuticals(MIRM.US), With a Forecast Between $145 to $185
  \u5e02\u573a\u8d44\u8baf · 2026/6/15
• 评级变动
  H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140
  \u5e02\u573a\u8d44\u8baf · 2026/8/21
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Mirum Pharmaceuticals (MIRM) and Hinge Health, Inc. Class A (HNGE)
  TipRanks · 2026/6/11
• 评级变动
  Morgan Stanley Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $150
  \u5e02\u573a\u8d44\u8baf · 2026/6/16
• Citi Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $160
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Cuts Target Price to $118
  \u5e02\u573a\u8d44\u8baf · 2026/8/7
• J.P. Morgan Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/9/29

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。